16-18 July 2018 | Boston


Workshop A
Monday, July 16th 2018

09.00 - 12.00
Modelling of Compound Combination Effects and Applications to Cancer Drug Efficacy and Toxicity

An unprecedented range of combination approaches are currently under investigation, but without robust preclinical validation backing the mechanism of action of these strategies, many of these studies will fail to reach their clear potential. This interactive workshop will incorporate insights into a range of in vivo modelling approaches, providing you with the valuable tools to enhance your preclinical development. This session aims to provide a comprehensive overview of preclinical strategies, including insights that will allow attendees to improve the robustness of their preclinical approach

Join this session to explore:

  • How models can replicate a more natural and translationally relevant tumor microenvironment
  • The situations in which syngeneic mice, GEMMs and strategies of immune system humanization in mice can add most value to preclinical development
  • The predictive validity, efficacy and safety of humanized mouse models

Workshop Leaders
Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic

Workshop B
Monday, July 16th 2018

09.00 - 12.00
Next Generation Patient Avatar Systems to Maximize Immunotherapy Benefits
Workshop Leader: Hon Leong, Associate Associate ProfessorProfessor, Mayo Clinic

Despite numerous drug options available, clinicians often do not have the right biomarkers to prescribe the right drug to the right patient. This session will introduce the concept of using patient derived specimens (primary tumor or metastases) and their implantation into non-murine models such as the chick embryo to guide drug selection in kidney and prostate cancer.

Join this session to explore how:

  • Implantation of biopsies or tumor fragments from the primary or metastasis into chick embryos results in intact and viable immune cells carried over from the patient.
  • Injection of immunotherapies or targeted therapies is performed to determine if an anti-tumor effect is observed using immunophenotyping and high frequency ultrasound imaging.
  • Tumor heterogeneity studies can be performed, enabling a comprehensive evaluation of the patient’s tumor burden upon drug challenge.
  • Responses occur within 7 days of implantation with fold increases in tumor infiltrating lymphocytes observed that appear to be “exhausted”.

Workshop Leaders
Hon Leong, Associate Professor, Mayo Clinic

Hon Leong, Associate Associate ProfessorProfessor, Mayo Clinic

Workshop C
Monday, July 16th 2018

15.00 - 18.00
Advances in Utilizing Humanized Mice to Model Human T Cell Responses

Checkpoint-based therapeutics have solidified their place as the next wave of IO therapies. Despite an unprecedented range of mono and now combination approaches currently in clinical development, robust preclinical validation is lacking for many. This session will explore the a variety of models at our fingertips as well as well as the need effectively evaluate compound MOA as well as Comprehending the mechanisms of heterogeneity and the patterns of divergence in tumor subtypes.

Join this session to explore:

The relative advantages of the range of in vivo models available to develop IO therapeutics

  • How models can replicate a more natural and translationally relevant tumor microenvironment and enable the effective preclinical characterization and pharmacodynamic evaluation of agonists
  • How we should minimize the likelihood for current and novel checkpoint inhibition strategies to fail due to tumor escape
  • Discern combinatorial approaches of pathways to enhance antitumor responses to ICIs, and chemotherapeutic agents

Workshop D
Monday, July 16th 2018

13.00 - 16.00
Tackling Resistance, Examining The Drug Responses Of Cancer Stem Cells In The Context Of Their Niche
Workshop Leader: Esmaiel Jabbari, Professor of Chemical & Biomedical Engineering, University of South Carolina

Cancer heterogeneity is not only generated by genetically distinct sub clones within each tumour, but also driven by phenotypic and functional heterogeneity within each of these sub clones. These epigenetically defined phenotypes are responsible for intraclonal heterogeneity including a functionally defined subset of so-called cancer stem cells (CSCs).
Essential for the metastatic behaviour of tumours and, due to their inherent chemoresistance they represent an important source for disease relapse as
such drug targeting.
This session aims to provide an insight into the role and importance of CSC’s as well as strategies and advances in their targeting.

Join this session to explore:

  • Preclinical models in the development of therapies targeting cancer  stem cells
  • Exploring TAM-CSC tumor tissue models as an ideal platform for  preclinical drug efficacy evaluation for cancer stem cells
  • The Utility of CSC’s for modelling resistance given their metastatic behaviour inherent chemo resistance
  • Highlighting experimental results related to the effect of immune infiltrate on toxicity within the three-dimensional CSC culture system
  • Presenting high-throughput strategies

Esmaiel Jabbari, Professor of Chemical & Biomedical Engineering, University of South Carolina

Dr. Jabbari is a Tenured Full Professor of Chemical and Biomedical Engineering and the Director of Biomaterials, Tissue Engineering and Drug Delivery at the University of South Carolina. He earned his Ph.D. from Purdue University in Chemical Engineering. Jabbari’s research is focused on engineering 3D multi-cellular co-culture systems to study and the effect of factors in the microenvironment on  function and fate of stem cells in tissue regeneration and cancer therapy. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of AIMBE in 2013. He has published >250 books, book chapters, refereed journal articles (107 peer-reviewed), and conference proceedings, and presented >260 seminars at national and international conferences (67 plenary, keynote, and invited seminars).